Recent advances in immunotherapy for the treatment of prostate cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 8, 2011, Pages 997-1009

  Sonpavde, Guru ^a,b   Agarwal, Neeraj ^c   Choueiri, Toni K ^d,e   Kantoff, Philip W ^d,e  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CTLA 4; immunotherapy; PD 1; prostate cancer; PROSTVAC VF TRICOM; sipuleucel T

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BPX 101; CANCER VACCINE; CV 9103; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DNA VACCINE; DOCETAXEL; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; IPILIMUMAB; L ANTIGEN FAMILY MEMBER 1; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PROSTATE SPECIFIC MEMBRANE ANTIGEN; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PREDNISONE; PROSTVAC VF TRICOM VACCINE; PROVENGE; RNA VACCINE; SOBLIDOTIN; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPOPHYSITIS; IMMUNE SYSTEM; IMMUNOREGULATION; INJECTION SITE REACTION; KIDNEY CARCINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POXVIRUS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SOLID TUMOR; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

POXVIRIDAE;

EID: 79959861428     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.575357     Document Type: Review

References (100)

1. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20 (Pubitemid 39315318)
3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
4. De Bono J, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel based chemotherapy: results of COU-AA-301, a randomized double blind placebo-controlled phase III study. Late Breaking Abstract 5, ESMO Congress, Milan October 2010
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
6. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-5
7. van Luijn MM, Chamuleau ME, Ressing ME, et al. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunol Immunother 2010;59:1825-38
8. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619
9. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60 (Pubitemid 38680426)
10. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011;18:23-34
11. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007;178:1975-9 (Pubitemid 46233392)
12. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007;56:81-7 (Pubitemid 44812449)
13. Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-6; discussion 686-7
14. Zhang H, Melamed J, Wei P, et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003;3:2
15. Kusmartsev S, Vieweg J. Enhancing the efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol 2009;6:540-9
16. Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol Med 2011;17:47-55
17. Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995;87:280-5
18. Filella X, Alcover J, Zarco MA, et al. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 2000;44:271-4
19. Elsasser-Beile U, Gierschner D, Jantscheff P, et al. Different basal expression of type T1 and T2 cytokines in peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Anticancer Res 2003;23:4027-31 (Pubitemid 37474360)
20. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
21. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8:618-31
22. Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000;85:451-62 (Pubitemid 30142622)
23. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22 (Pubitemid 41820645)
24. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008;222:206-21 (Pubitemid 351430372)
25. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins,and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s
26. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13:5271-9 (Pubitemid 47510350)
27. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985-94 (Pubitemid 39446933)
28. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47 (Pubitemid 36682620)
29. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9 (Pubitemid 47517504)
30. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptibleto vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37 (Pubitemid 38802440)
31. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007;150:523-30 (Pubitemid 350098743)
32. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87 (Pubitemid 43259871)
33. Wada S, Yoshimura K, Hipkiss EL, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009;69:4309-18
34. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010;33:639-47
35. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98:14565-70 (Pubitemid 33121432)
36. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7:239-49 (Pubitemid 40568683)
37. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957-71
38. Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175:2741-53 (Pubitemid 41113891)
39. Koh YT, Gray A, Higgins SA, et al. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009;69:571-84
40. Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174:539-46 (Pubitemid 40981596)
41. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-93
42. Sonpavde G, Slawin KM, Spencer DM, Levitt JM. Emerging vaccine therapy approaches for prostate cancer. Rev Urol 2010;12:25-34
43. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cellimmunotherapy: mapping the way. Nat Med 2004;10:475-80
44. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18(23):3894-903
45. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94 (Pubitemid 46638945)
46. Hanks BA, Jiang J, Singh RA, et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005;11:130-7 (Pubitemid 40321347)
47. Lapteva N, Seethammagari MR, Hanks BA, et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res 2007;67:10528-37 (Pubitemid 350070829)
48. Iuliucci JD, Oliver SD, Morley S, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 2001;41:870-9 (Pubitemid 32692098)
49. Park D, Lapteva N, Seethammagari M, et al. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 2006;24:1581-90 (Pubitemid 44967484)
50. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol 2005;32:549-55 (Pubitemid 41772682)
51. Harrington LE, Most Rv R, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002;76:3329-37 (Pubitemid 34224535)
52. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122-32 (Pubitemid 41095145)
53. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105
54. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7 (Pubitemid 46606398)
55. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74
56. Arlen PM, Gulley JL, Parker C, et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9 (Pubitemid 43342517)
57. Madan RA, Mohebtash M, Arlen PM, et al. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2010;28:15s (suppl; abstr 2550)
58. Vergati M, Intrivici C, Huen NY, et al. Strategies for cancer vaccine development. J Biomed Biotechnol 2010;2010 pii: 596432. 2010 Jul 11 [Epub ahead of print]
59. Best SR, Peng S, Juang CM, et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009;27:5450-9
60. Pasquini S, Xiang Z, Wang Y, et al. Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol 1997;75:397-401 (Pubitemid 27408048)
61. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005;6:593-9 (Pubitemid 41710730)
62. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91:688-94 (Pubitemid 39141625)
63. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009;27:4047-54
64. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010;33:639-47
65. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophagecolony- stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13:3883-91 (Pubitemid 47037595)
66. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975-84
67. Small E, Demkow T, Gerritsen, WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7]. Proceedings Genitourinary Cancer Symposium February 2009, Orlando, FL.(2009). Available from:
68. Cell Genesys Halts VITAL-2 GVAXTrial in Advanced Prostate Cancer. 2008. Available from: [Last accessed 24 March 2011]
69. Gerritsen W, Van Den Eertwegh, AJ, De Gruijl TD, et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (MHRPC) [abstract]. Prostate Cancer Symposium, Orlando, Florida; 2007
70. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003;3:10
71. Zeng G, Wang X, Robbins PF, et al. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 2001;98:3964-9
72. Zeng G, Li Y, El-Gamil M, et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002;62:3630-5 (Pubitemid 34728837)
73. CureVac Presents Convincing Data from the First Ever Phase I/IIa Clinical Study with a mRNA Based Vaccine. Strong Results in Safety, Tolerability and Biological Activity. Press Release: 4 October, 2010. Available from: http://www.drugs.com/clinical-trials/curevac-presentsconvincing-data-first-ever- phase-iiaclinical-study-mrna-based-vaccine-10258.html [Last accessed 24 march 2011]
74. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
75. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007;7:1245-56 (Pubitemid 47305249)
76. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958-64 (Pubitemid 46340373)
77. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-34 (Pubitemid 40116901)
78. Harris TJ, Hipkiss EL, Borzillary S, et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008;68:1319-29
79. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96 (Pubitemid 40216472)
80. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 2005;17:133-44 (Pubitemid 40246578)
81. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilatedcardiomyopathy in PD-1 receptordeficient mice. Science 2001;291:319-22 (Pubitemid 32096320)
82. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75
83. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33 (Pubitemid 43121851)
84. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26:2147-54
85. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31 (Pubitemid 41103739)
86. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601 (Pubitemid 46224061)
87. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-7 (Pubitemid 350002961)
88. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26:2147-54
89. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-6
90. Ma Q, Safar M, Holmes E, et al. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004;61:12-25 (Pubitemid 39095692)
91. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
92. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59
93. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179:2181-5; discussion 2185-2186
94. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9
95. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010;102:1388-97
96. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
97. Arlen P, Tsang KY, Marshall JL, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-29
98. Whiteside TL. Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense. Immunol Invest 2000;29:149-62 (Pubitemid 30316957)
99. Kreher CR, Dittrich MT, Guerkov R, et al. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J Immunol Methods 2003;278:79-93 (Pubitemid 37281194)
100. Molldrem JJ, Lee PP, Wang C, et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81 (Pubitemid 29269115)